

# Special Issue

## Feature Paper in Section "Cancer Biomarkers" in 2022

### Message from the Guest Editors

This Special Issue will include high quality, high impact papers in the field of Cancer Biomarkers. Advances in the research of any type of malignancy that provide evidence for cancer biomarkers in the effort to improve cancer patient diagnoses, management, and outcomes are welcome.

---

### Guest Editors

Dr. Carlos S. Moreno

1. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA

2. Department of Biomedical Informatics, Emory University, Atlanta, GA 30322, USA

3. Department of Urology, Emory University, Atlanta, GA 30322, USA

Dr. Dolores Di Vizio

Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

---

### Deadline for manuscript submissions

closed (15 September 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/101842](https://mdpi.com/si/101842)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)